BEIJING, Feb. 08, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (“BeiGene” or “the Company”), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced the closing of its initial public offering of 7,590,000 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at an initial public offering price of $24.00 per ADS, before underwriting discounts. This includes the full exercise of the underwriters’ option to purchase additional ADSs. All of the ADSs in the offering were offered by BeiGene. The ADSs are listed on The NASDAQ Global Select Market under the ticker symbol “BGNE.”

Goldman, Sachs & Co., Morgan Stanley, and Cowen and Company acted as joint book-running managers. Baird acted as co-manager of the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 2, 2016. The offering was made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY  10282, telephone: 1-866-471-2526, or email: prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; or Cowen and Company, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY  11717, United States, Attn.: Prospectus Department or by calling +1 (631) 274 2806.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About BeiGene

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

Media/Investor Contact:

Xin Huang
US: +1 917-617-4653
China: +86 185-1406-3050
pr@beigene.com

Source: BeiGene Ltd.